PURPOSE: To report toxicity, prognostic factors, and outcome of HDR brachytherapy in the primary management of vaginal carcinoma. METHODS AND MATERIALS: A total of 86 patients receiving radiotherapy for primary vaginal carcinoma were analyzed. FIGO stages 0-IV were found in 6, 17, 38, 20, and 5 patients, respectively. Early stages of disease (Stages 0-II) were treated with intravaginal HDR brachytherapy alone (n = 26/86), whereas locally advanced diseases (Stages II-IV) received HDR brachytherapy combined with external beam therapy (n = 55/86). Teletherapy only was used in 5 of 86 cases, all of which were treated with palliative intent (i.e., advanced stage, poor general status). Recurrence-free intervals as well as overall- and disease-specific survival rates were determined for all patients. Frequencies of side effects and the influence of prognostic factors and treatment modalities on outcome were analyzed. RESULTS: Five-year overall survival rates for Stages 0-IV diseases were 83%, 41%, 43%, 37%, and 0%, respectively. Corresponding 5-year disease-specific survival rates were 100%, 92%, 57%, 59%, and 0%. Regarding 5-year recurrence-free intervals, values of 100%, 77%, 50%, 23%, and 0% (Stages 0-IV) were found, respectively. Tumor stage was the most significant prognostic factor. Chronic side effects G 1-4 were observed in <or=2% (bladder, rectum) and 1%-6% (vagina). CONCLUSION: In the treatment of primary vaginal carcinoma, HDR brachytherapy appeared to be well-tolerated and as effective as LDR brachytherapy techniques.
PURPOSE: To report toxicity, prognostic factors, and outcome of HDR brachytherapy in the primary management of vaginal carcinoma. METHODS AND MATERIALS: A total of 86 patients receiving radiotherapy for primary vaginal carcinoma were analyzed. FIGO stages 0-IV were found in 6, 17, 38, 20, and 5 patients, respectively. Early stages of disease (Stages 0-II) were treated with intravaginal HDR brachytherapy alone (n = 26/86), whereas locally advanced diseases (Stages II-IV) received HDR brachytherapy combined with external beam therapy (n = 55/86). Teletherapy only was used in 5 of 86 cases, all of which were treated with palliative intent (i.e., advanced stage, poor general status). Recurrence-free intervals as well as overall- and disease-specific survival rates were determined for all patients. Frequencies of side effects and the influence of prognostic factors and treatment modalities on outcome were analyzed. RESULTS: Five-year overall survival rates for Stages 0-IV diseases were 83%, 41%, 43%, 37%, and 0%, respectively. Corresponding 5-year disease-specific survival rates were 100%, 92%, 57%, 59%, and 0%. Regarding 5-year recurrence-free intervals, values of 100%, 77%, 50%, 23%, and 0% (Stages 0-IV) were found, respectively. Tumor stage was the most significant prognostic factor. Chronic side effects G 1-4 were observed in <or=2% (bladder, rectum) and 1%-6% (vagina). CONCLUSION: In the treatment of primary vaginal carcinoma, HDR brachytherapy appeared to be well-tolerated and as effective as LDR brachytherapy techniques.
Authors: Altamiro Ribeiro Dias; Marcela Cavalcante de Andrade Silva; Filomena Marino Carvalho; Heloisa de Andrade Carvalho; Maria Del Pilar Esteves Diz; Edmund Chada Baracat; Jesus Paula Carvalho Journal: Rare Tumors Date: 2012-01-02
Authors: Deepinder P Singh; Kevin C Bylund; Ahmad Matloubieh; Ali Mazloom; Alexander Gray; Ravinder Sidhu; Lucille Barrette; Yuhchyau Chen Journal: J Contemp Brachytherapy Date: 2015-04-28
Authors: Sushil Beriwal; Dwight E Heron; Robert Mogus; Robert P Edwards; Joseph L Kelley; Paniti Sukumvanich Journal: Radiat Oncol Date: 2008-02-13 Impact factor: 3.481
Authors: Ji Hyun Chang; Won Il Jang; Yong Bae Kim; Jin Hee Kim; Young Seok Kim; Yeon Sil Kim; Won Park; Juree Kim; Won Sup Yoon; Joo-Young Kim; Hak Jae Kim Journal: J Gynecol Oncol Date: 2016-03 Impact factor: 4.401